AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform ...

Ardigen’s AI and computational biology capabilities will strengthen VERAXA’s in-house AI efforts to optimize cancer target pair selection for conditionally active T cell engagers and antibody-drug ...

IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully ...

Xencor is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology.

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support ...

Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34 million) investment from the British Business Bank - the Bank's largest investment in a ...

iBio, Inc., an innovator in precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment program by in-licensing a long-acting anti-myostatin antibody, ...

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of ...

OXFORD, England--(BUSINESS WIRE)--British techbio innovator Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody ...

Karim Dabbagh, Ph.D., joins as CEO, bringing leadership experience in advancing immunology and inflammation therapies through clinical trials; Rich Murray, Ph.D., former interim CEO, remains on the ...